ClinVar Miner

Submissions for variant NC_012920.1(MT-TA):m.5610G>A

dbSNP: rs786200951
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Mitochondrial Disease Nuclear and Mitochondrial Variant Curation Expert Panel, ClinGen RCV004691104 SCV005187330 uncertain significance Mitochondrial disease 2024-02-12 reviewed by expert panel curation The m.5610G>A variant in MT-TA has been reported in one individual with primary mitochondrial disease to date, in a 69-year-old woman with progressive limb girdle muscle weakness, dysarthria, and myopathic facies. Ragged red fibers and COX-negative fibers were noted on muscle biopsy. The variant was present at 91% heteroplasmy in muscle and 87% heteroplasmy in blood (PMID: 25873012). The variant was present at lower (9-26% heteroplasmy) to undetectable levels in healthy family members although this expert panel notes some of these family members were not yet the age of the proband when she began to experience symptoms (PP1; PMID: 25873012). There are no reported de novo occurrences of this variant to our knowledge. This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting). Single fiber testing showed higher levels of the variant in COX-negative fibers (98%; n=20) than in COX-positive fibers (78%; n=21, P = 0.0002; PS3_supporting, PMID: 25873012). Additionally, studies have shown decreased steady-state levels of tRNA Alanine in muscle from the proband (PMID: 25873012). Computational predictors are discordant as MitoTIP suggests this variant is benign (38.7 percentile) and HmtVAR predicts it to be pathogenic (0.55). Of note, this variant is highly conserved among primates at 83%. In summary, this variant meets criteria to be classified as uncertain significance for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on February 12, 2024. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PP1, PM2_supporting, PS3_supporting.
Wellcome Centre for Mitochondrial Research, Newcastle University RCV000169781 SCV000196083 pathogenic Inborn mitochondrial myopathy 2014-12-15 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.